Shares of Hinge Health (HNGE) continued their upward momentum in Thursday's premarket session, adding 0.4% to $38.90. This modest gain builds on a substantial 17.3% surge during Wednesday's regular trading, a rally primarily fueled by the company's robust financial outlook for 2026.
Strong Forward Guidance Drives Investor Confidence
The digital musculoskeletal care provider issued a revenue forecast for the full year 2026 projecting between $732 million and $742 million. This forward-looking statement followed the release of impressive fourth-quarter 2025 results, which showed revenue climbing 46% year-over-year to $170.7 million. On an adjusted basis, diluted earnings per share for the quarter came in at $0.49. For the upcoming first quarter, management anticipates revenue in the range of $171 million to $173 million, with an adjusted operating margin, excluding certain items like stock-based compensation, projected around 18% at the midpoint.
Analyst Sentiment and Valuation Metrics
In reaction to the earnings report, RBC Capital Markets maintained its Outperform rating on HNGE stock but reduced its price target to $50 from a previous $60. The firm cited "another solid quarter of revenue outperformance and margin expansion" as positive factors, while also noting the stock's current valuation at approximately three times its projected 2027 revenue. RBC analysts emphasized that the company possesses "a long runway ahead" as it expands into a larger addressable market.
Hinge Health, which provides digital solutions for joint and muscle pain to employers and health plans, went public in May 2025 with an initial offering price of $32. Its performance is being closely watched as a barometer for investor appetite in the health technology IPO sector, which has experienced a prolonged period of limited new listings. The recent rally suggests investors are rewarding companies that demonstrate disciplined growth, accelerating revenue, improving margins, and strategic initiatives like share repurchases.
GAAP vs. Non-GAAP: A Critical Distinction
Despite the positive adjusted profitability metrics, the company's filings revealed a significant GAAP operating loss for the full year 2025. This divergence between GAAP (Generally Accepted Accounting Principles) results and the adjusted non-GAAP figures highlighted by management presents a key consideration for investors. The pace at which this gap closes will likely be a major factor influencing the stock's trajectory, especially given its inherent volatility since its market debut.
CEO Daniel Perez characterized the fourth quarter as "exceptional," attributing the success to higher customer win rates and an increase in eligible lives under management by year-end. The company has submitted its quarterly results via an SEC Form 8-K filing, with the comprehensive annual Form 10-K expected to be filed in the coming weeks. The next scheduled earnings update is set for May 7, 2026.
The market's reaction underscores a renewed focus on post-IPO companies that can deliver on growth promises while maintaining operational discipline. For Hinge Health, the path forward involves balancing its impressive top-line expansion with the journey toward consistent profitability under standard accounting measures, a challenge that will remain in the spotlight for the foreseeable future.
